BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Interviews » Page 14

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Improving Access to Donor- and Disease-Specific Stem Cells – Interview with Alec Lee of Extem Bioscience

January 17, 2016 By Cade Hildreth (CEO)

Q&A Interview with Alec Lee of Extem Biosciences

Extem BioscienceThis is an interview with Alec Lee, Head of Business Development at Extem Bioscience, an innovative stem cell company that has developed a new device and process to purify and expand adult stem cells in greater numbers.

The company is focused on the isolation, rapid purification, and expansion of adult mesenchymal stem cells (MSCs). Enjoy these insights into Extem’s future strategies and directions.

Interview with Alec Lee of Extem Bioscience

Cade Hildreth: How and when was Extem founded?

Alec Lee: Extem was founded in 2014 in Vancouver, British Columbia, and now based in San Francisco, California.

Cade Hildreth: How was your team of founders formed?

Alec Lee: The founders – Mardonn, Darson, and Alec – were all alumni of the Biotechnology Program at the University of British Columbia. Mardonn Chua (CEO) conceived the idea as a researcher at Columbia University, as a way to enable his lab to regularly work with primary stem cells.

Darson (CSO) is responsible for experimental design and process development. His experience working as a QA and QC Inspector in industry enables the team to uphold the level of product quality customers expect.

Alec Lee is a Harvard Business School student and oversees the business development and strategic play of the venture.

Mike Bowles (Machine Learning) builds our learning algorithms. He was the co-founder of Com 21, iBeam, and was professor of Machine Learning – Control and Estimation Theory at MIT.

Cade Hildreth: What is the core technology on which Extem is based?

Alec Lee: The core technology is based on two parts – first, the rapid purification and expansion of adult stem cells without genetic manipulation, and second, the development of analytical models of stem cell differentiation based on machine learning algorithms.

On the production end, Extem has developed a new device and process to purify and expand adult stem cells, specifically MSCs at greater numbers. This allows us to provide researchers in academia and industry with improved access to donor- and disease-specific stem cells.

Cade Hildreth: How does Extem differ from other mesenchymal stem cell (MSC) companies?

Alec Lee: Extem’s technology is comprised of a production core and computational biology core. While traditional MSC (and other stem cell) companies offer only marginal improvements in stem cell growth, we are the first stem cell company developing predictive models of stem cell differentiation – i.e. being able to predict, to a certain degree, how well a donor or patient’s cells form into bone or cartilage tissue.

Extem Bioscience

We believe that our two-core technology provides a more robust approach to evaluating the efficacy of MSCs not just for basic research, but also for pre-clinical drug development. At the outset, our system provides our clients with therapeutic-centric data.

Cade Hildreth: Have you filed for or are you pursuing intellectual property (IP) positions?

Alec Lee: Yes, the company has filed a provisional patent on our production process. We are currently developing IP for our machine learning systems.

Cade Hildreth: What are your near-term (3-5 year) goals?

Alec Lee: We have three main goals in the near term: first, to expand our bank of stem cells to 100 donors, second, to complete the next version of our machine learning algorithms for osteogenic, adipogenic, and chondrogenic differentiation, and third, to work with clinicians in assessing the predictive power of our algorithms in stem cell-based therapeutic applications.

Cade Hildreth: Do you anticipate seeking out partnerships or investors for Extem Bioscience?

Alec Lee: Yes, we have raised venture capital to fund initial operations and anticipate raising further investment for future R&D.

Cade Hildreth: Do you foresee yourselves staying a MSC-specific company or expanding into other stem cell types?

Alec Lee: Expanding to different stem cell types (e.g. hematopoietic stem cells and even induced pluripotent stem cells) is on our timeline. We have specifically developed our tech to be tractable for other stem cell types.

Cade Hildreth: Thank you for the honor of doing this interview and for sharing insights into your innovative MSC products.

To learn more about Extem Biosciences, visit www.ExtemBio.com or connect with Alec Lee on LinkedIn.

Filed Under: Interviews, MSCs, Stem Cells Tagged With: Extem Biosciences, interview, market news, mesenchymal stem cells, Q&A, stem cells

ORIG3N, World’s Largest Blood Cell Repository for iPS Cell Production

December 12, 2015 By Cade Hildreth (CEO)

ORIG3N iPS Cells

ORIG3N LogoORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell / iPSC) production. When James Lovgren, Chief Business Officer of ORIG3N, and I met at the World Stem Cell Summit, we intended to explore potential collaborations and synergy between our companies. Instead we had an inspired conversation about the global importance of iPS cells, stem cell market dynamics, and the importance of social platforms to the stem cell community.

I was so inspired by ORIG3N’s vision that I took advantage of the opportunity to interview Mr. Lovgren. [Read more…]

Filed Under: Interviews, iPS Cells, Stem Cells Tagged With: interview, iPSC, James Lovgren, market news, Orig3n, Q&A, stem cells

Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories

September 11, 2015 By Cade Hildreth (CEO)

Perinatal Stem Cell Conference

AuxocellThis is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society  Conference that will take place March 2-4, 2016 in Aspen, CO.
[Read more…]

Filed Under: Cord Blood, HSCs, Interviews, MSCs Tagged With: Auxocell, Kyle Cetrulo, perinatal

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

CellSource

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source’s Scientific Advisory Board

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

Dr. John Sessions

The American Academy of Stem Cell Physicians Pays Tribute to Dr. John Sessions, “Everyone’s Teacher”

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.